Chronic Lymphocytic Leukemia

Robert L. Ferris, MD, PhD, co-physician editor in chief of Targeted Therapies in Oncology, discusses exciting new findings and merit highlights reported in this month's issue.

Presentations at the 60th American Society of Hematology Annual Meeting & Exposition were dominated by advancements in the treatment of chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.

Lead iLLUMINATE study author Carol Moreno, MD, PhD, discusses the safety and efficacy results from the iLLUMINATE trial which led to the FDA approval of ibrutinib plus obinutuzumab in CLL.

Matthew S. Davids, MD, MMSc, discusses findings from an updated analysis of the phase III DUO study in patients with CLL.

A look back at all the FDA news in oncology from the month of January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

In an interview with <em>Targeted Oncology</em>, Ian W. Flinn, MD, PhD, discussed the potential impact of duvelisib&nbsp;on patients with CLL. Flinn serves as the lead investigator of the DYNAMO and DUO studies in duvelisib.

Treating An Elderly Woman with Chronic Lymphocytic Leukemia

The combination of ibrutinib and obinutuzumab has gained FDA approval for the first-line treatment of patients with&nbsp;chronic lymphocytic leukemia or small lymphocytic lymphoma, based&nbsp;on data from the phase III iLLUMINATE trial.

Treatment for Relapsed Chronic Lymphocytic Leukemia

Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.

A triplet regimen consisting of chlorambucil and rituximab in combination with an individualized dose of lenalidomide can potentially be used as a frontline treatment for patients with advanced chronic lymphocytic leukemia who are older or unfit for standard treatment with fludarabine, cyclophosphamide, and rituximab.